Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches targeting worldwide unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs which could be from plant materials, algae, macroscopic fungi, and combinations thereof. This strategy is supported by FDA set of regulatory guidelines, favouring a more efficient drug development pathway for prescription botanical drug products.
Botanical Drug: Source of new products for the pharmaceutical industry
➢ Faster and Less Costly Drug Development from Pre-Clinical to Proof-of-Concept study (Phase 2);
➢ Superior Risk Management;
➢ Botanical drugs are cleared for specific indications just like a regular drug;
➢ Botanical drugs are coded and accessible for medication reimbursement plans;
➢ Marketing exclusivity for up to 5 years even in the absence of patent protection;
➢ ‘’Copy-cat’’ proof.
André P. Boulet, Ph.D.
President & Chief Executive Officer
Dr André Boulet has a vast experience in drug development, regulatory affairs, market access, financing and restructuration in the pharmaceutical and biotech fields. A seasoned entrepreneur, he stands out by combining his strengths in applied science, business and finance.
Since 2005, he has been leading the development of the technology and products own by Devonian Health Group. He raised more than $40M in private/public equity, completed phase 1 and phase 2 ulcerative colitis clinical program for the company`s flagship product Thykaminetm as well as a complete line of patent-pemding anti-aging products for women.
Prior to this endeavour, he was a managing partner of SIPAR’s biotech unit, a $400M private investment firm. Prior to SIPAR, Dr Boulet was partner at BioCapital III LP (« BioCapital ») (1996-2002), a Canadian biotech venture capital company. At BioCapital, he was responsible for investment strategy, deal development, analysis, valuation and negotiation of selected investments. BioCapital had substantial success during his association with the fund: from 1997 to 2001 (when the fund was wound up), the fund generated a 19.75% IRR (net) to each unitholder.
Throughout his career, Dr Boulet acquired an international expertise in drug development, regulatory affairs and health economics within Hoechst Marion Roussel, Marion Merrell Dow Canada and Laboratoires Nordic ( Sanofi-Aventis).
Dr Boulet is Editor in Chief of the Journal of Dairy, Veterinary & Animal Research. He is also a member of the Editorial Boards of Biomedical Journal of Scientific and Technical Research and of MOJ Autoimmune Disease.
Dr Boulet holds a Bachelor’s Degree in Medical Biology from University of Quebec in Trois-Rivieres, a Master’s Degree in experimental medicine/immunology-immunochemistry as well as a PhD in physiology-endocrinology from Laval University in Quebec City. He also did a post-doctorate training at University of Pennsylvania (USA) in biochemistry-biophysics and a training program in Health Economics at York University (UK).
Colette Laurin, CPA, CA
Interim Chief Financial Officer
Prior to joining Devonian in 2015, Ms. Laurin was a corporate and corporate finance consultant and, for over 16 years, acquired experience in a wide range of banking sectors. She has held a number of positions at the National Bank of Canada, including Business Credit Manager, Business Center Director, and has managed to integrate and support the administrative tasks of nearly 35 bank branches, management responsibility of more than 120 employees. She has also held the position of Director of Development of the Inspection Department and Internal Audit. Prior to this, she held the position of auditor at Raymond, Chabot Martin Paré (now Raymond Chabot Grant Thornton).
Nathalie Boucher, Ph.D.
Director, Research and Intellectual Property
Nathalie Boucher holds a bachelor’s degree in biochemistry, a master’s degree in biophysics, and a Ph.D. in environmental science (with a specialization in toxicology). She has many years of experience in both private and university research centers and stands out for her expertise in plant physiology, plant cell extraction, and enzyme stabilization. She has also contributed to the writing of numerous patents and scientific articles.
Dr André P. Boulet, Ph.D.
President & Chief Executive Officer
Jacques Bernier, B.Pharm, MBA – Director
Jacques Bernier has been part of FOLIA BIOTECH team from its inception and acted as its CEO from 2008 to 2014 after several successful years in the business world. He was responsible for establishing FOLIA’s Business Plan with a new vision. He raised more than $11.0 M in funding. Under his leadership, the company successfully completed the preclinical program and the first clinical trial in human (Phase I) of its lead product FB-631. In addition, the company has developed research collaborations with many companies or organizations. Since 2014 he is member of the Board of FOLIA as a Director and Chair of the finance and audit committee.
Before joining FOLIA BIOTECH, he was President and CEO of Gescopharm Inc a company involved in the operation of retail pharmacy. During these years, he gained extensive experience in management and business development and an excellent knowledge of the pharmaceutical industry. He was a member of the Board of Familiprix a group of nearly 300 pharmacies. First, as member of the marketing committee for advertising, marketing and sales strategy and then Vice President of the Board and Vice President of the Finance committee where he was responsible for budget and financial statements of the company.
He holds a Bachelor’s Degree in pharmacy from Université Laval, Quebec City (1984). In 2007, he completed his MBA with a concentration in pharmaceutical management at Université Laval. Within this program, he gained a distinctive competence of managing organizations in the pharmaceutical field, as the biotechnology sector. In 2008, he completed a graduated program in pharmaceutical product development. This training allowed him to get familiar with each steps of the clinical process, from pre-clinical testing to phase IV clinical studies.
He is a member of the Board and Treasurer of Montmagny Hospital Foundation. He is a member of committees for several charitable activities.
Borys Chabursky – Director
Mr. Borys Chabursky specializes in strategic planning, fundraising, financial management and business development for biotechnology, medical device, imaging and oncology companies and science and technology incubators in both the public and private sector. As the founder and Chairman of Shift Health, he has overseen the successful completion of over 500 life sciences assignments for more than 300 clients in North America, Europe and the Middle East; the development of compelling business cases and implementation plans that have helped leverage over $1B in financing from private and public sector resources; and the creation and facilitation of more than 50 public-private partnerships in biomedical research, infrastructure development and global health. Mr. Chabursky has worked closely with industry thought leaders, large pharmaceutical companies, government agencies, hospital boards and healthcare networks. He has also provided interim management for seven start-up companies and angel financing for ten new start-up ventures. With his experience spearheading large-scale, multi-stakeholder, global initiatives, Mr. Chabursky often serves as an advisor to influencers and developers of government policy.
Pierre Colas – Director
Mr. Colas has experience in the field of corporate finance. Retired Québec based investment banker, Mr. Colas was Vice President and Managing Director, Investment Banking at Industrial Alliance Securities Inc., a corporation who offers a diversified business ranging from wealth management, institutional equity research and institutional bonds to group pensions, from March 2009 to February 2014. Prior to his appointment at Industrial Alliance Securities Inc., he was Senior Vice President, Investment Banking at Desjardins Securities Inc., a corporation who offers a complete range of securities brokerage products and services through its investment advisors and its Disnat Online Brokerage division, from April 2005 to March 2009. Mr. Colas holds a bachelor degree in commerce from the Concordia University, Montréal since May 1980. He was a member of the TSX Advisory Committees.
Sybil Dahan – Director
Biochemist by education, Mrs. Sybil Dahan began her career in the pharmaceutical industry in 1989. She held many positions in Sales and Marketing in Canada. She spent most of her career with Abbott Laboratories (now AbbVie) which lead her to work in the USA and Latin America, and then in Sweden as General Manager and Chairman of the Board of Abbott Scandinavia. Mrs. Dahan became one of the first foreign General Managers in Sweden to become an elected Board member of the Swedish Pharmaceutical Trade Association (LIF). She returned to Canada in 2008, but soon thereafter leaves Big Pharma to explore the world of small to medium size businesses. She joined Triton Pharma Inc. as President, and following the sale of Triton Pharma Inc. to Paladin Labs Inc. in December 2013, Mrs. Dahan embarks on the third phase of her career’s journey – entrepreneurship – to become co-owner of Aspri Pharma Canada Inc. and more recently Altius Healthcare; importer and distributor of pharmaceutical products managing over thirty million dollars of annual sales. Mrs. Dahan is recognized by her peers as being a visionary and energetic senior level leader who effectively manages all aspects of commercial operations.
Louis Flamand, PhD, MBA – Director
Louis Flamand, PhD, MBA, is a full professor and vice-chair of the department of microbiology-infectious-disease-immunology at the Faculty of medicine, Université Laval and senior researcher in the division of infectious and immune diseases at the CHU de Quebec research center. Before joining Laval university, Dr Flamand obtained his PhD at the University of Montreal and post-doctoral training that the National Institutes of Health and at the Institute of Human Virology (Maryland, USA). He received his MBA in pharmaceutical management from Université Laval. Since 2008, he is President of the biohazards risk committee at Université Laval. He is also member of the HHV-6 Foundation scientific advisory board since 2006. Dr Flamand has experience in pre-clinical development. Throughout his career, Dr Flamand has received several competitive scholarship awards and continuous funding support from several funding agencies for his work in virology. Dr Flamand is the author of more than 80 peer-reviewed publications and is lead Editor of the book “Human Herpesviruses HHV-6A, HHV-6B & HHV-7: Diagnosis and Clinical Management” 3rd edition.
Terry L. Fretz – Director
Currently President of Maricann Group Inc. (C.MARI), a publicly traded, international medical cannabis company, Mr. Terry L. Fretz is a long-time pharmaceutical executive. Mr. Fretz operated a successful consulting business focused on the healthcare sector, and held key leadership roles in the establishment and operating of two privately held generic pharmaceutical companies, including initiatives in international markets. During his tenure, both organizations were recognized as the fastest growing pharma companies in Canada. Both companies were subsequently acquired by publicly traded multinationals. Mr. Fretz served as President and General Manager of Watson Pharmaceuticals Company – Canada, and spent the earlier part of his career with publicly traded Rx&D companies Bristol-Myers Squibb Squibb Canada and Syntex.
Scientific Advisory Committee
Devonian is currently recruiting experts throughout the world to provide guidance and assistance for its botanical prescription drug development activities. These advisers will use their extensive experience in toxicology and preclinical and clinical development to help guide Devonian’s management team and ensure that its development activities are conducted according to state-of-the-art standards and meet all regulatory requirements. As part of this research, Dr. Jean-Claude Tardif, MD has accepted the position of Chairman of the Scientific Advisory Committee of the Company.
Dr Jean-Claude Tardif, MD, FRCPC, FACC, FCAHS
Chairman of Scientific Advisory Board
Jean-Claude Tardif is the Director of the Research Centre at the Montreal Heart Institute and Professor of Medicine at the University of Montreal. Dr. Tardif graduated from the University of Montreal with his medical degree in 1987 and completed his training in cardiology and research in Montreal and Boston in 1994. Dr. Tardif holds the Canada Research Chair in translational and personalized medicine and the University of Montreal endowed research chair in atherosclerosis. He is the Scientific Director of the Montreal Health Innovations Coordinating Centre (MHICC) and Chairman of the steering committees of the CIHR-funded Canadian Atherosclerosis Imaging Network (CAIN) and Medical Imaging Trials Network of Canada (MITNEC).
Dr. Tardif has authored and co-authored more than 800 articles and abstracts in peer-reviewed publications, including the New England Journal of Medicine, the Journal of the American Medical Association, The Lancet, Circulation, the Journal of the American College of Cardiology, the European Heart Journal, Nature Genetics, Genes and Development, the British Journal of Pharmacology, and Cardiovascular Research. In addition, he has written more than 30 book chapters (including in Braunwald’s Textbook of Heart Disease) and has edited several books. He has given approximately 400 invited lectures around the world.
His research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves pre-clinical models, mechanistic and observational clinical studies as well as large international randomized clinical trials. Dr. Tardif is or has been the international principal investigator or part of the study leadership of several large clinical trials in the field of atherosclerosis and other cardiovascular diseases.
Dr. Tardif and his team have created the Beaulieu-Saucier Pharmacogenomics Center at the Montreal Heart Institute and he has created the Center of Excellence in Personalized Medicine (CEPMed), the latter funded by the Network of Centers of Excellence (NCE) of Canada and which is also supported by multiple pharmaceutical and biotechnological companies. He is one of the founding fathers of the International Partnership for Critical Markers of Disease (CMOD) organization, which focuses on the development and better use of biomarkers (www.cmod.org).
Dr. Tardif has won multiple awards during his career, including the Research Achievement Award of the Canadian Cardiovascular Society, the Genesis Award of BIOQuebec (for his outstanding contributions to life sciences) and the Armand-Frappier Award of the Government of Quebec (the highest scientific distinction in Quebec). He was also named scientific personality of the year by La Presse newspaper. Because of his accomplishments, Dr. Tardif was named Fellow of the Canadian Academy of Health Sciences (FCAHS) and was recently inducted into the Order of Canada.